Abstract:WD repeat domain 5 (WDR5) is a core scaffolding component of many multiprotein complexes that perform a variety of critical chromatin-centric processes in the nucleus. WDR5 is a component of the mixed lineage leukemia MLL/SET complex and localizes MYC to chromatin at tumor-critical target genes. As a part of these complexes, WDR5 plays a role in sustaining oncogenesis in a variety of human cancers that are often associated with poor prognoses. Thus, WDR5 has been recognized as an attractive therapeutic target for treating both solid and hematological tumors. Previously, small-molecule inhibitors of the WDR5-interaction (WIN) site and WDR5 degraders have demonstrated robust in vitro cellular efficacy in cancer cell lines and established the therapeutic potential of WDR5. However, these agents have not demonstrated significant in vivo efficacy at pharmacologically relevant doses by oral administration in animal disease models. We have discovered WDR5 WIN-site inhibitors that feature bicyclic heteroaryl P7 units through structure-based design and address the limitations of our previous series of small-molecule inhibitors. Importantly, our lead compounds exhibit enhanced on-target potency, excellent oral pharmacokinetic (PK) profiles, and potent dose-dependent in vivo efficacy in a mouse MV4:11 subcutaneous xenograft model by oral dosing. Furthermore, these in vivo probes show excellent tolerability under a repeated high-dose regimen in rodents to demonstrate the safety of the WDR5 WIN-site inhibition mechanism. Collectively, our results provide strong support for WDR5 WIN-site inhibitors to be utilized as potential anticancer therapeutics.

Design, Synthesis, and Initial Evaluation of Affinity-Based Small Molecular Probe for Detection of WDR5.

Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with <i>in vivo</i> antitumor activity

A novel highly sensitive fluorescent probe for bioimaging biothiols and its applications in distinguishing cancer cells from normal cells.

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

Identification and Validation of WDR5 WIN-site Ligands Via DNA-encoded Chemical Library Screening

Structure-Based Design and Synthesis of Small Molecular Inhibitors Disturbing the Interaction of Mll1-Wdr5

Screening and Optimization of Phage Display Cyclic Peptides Against the WDR5 WBM Site

Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer

Identification of 5-Thiocyanatothiazol-2-amines Disrupting WDR5-MYC Protein-Protein Interactions.

Discovery of DDO-2213 As a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia

Computational Studies of Novel Aniline Pyrimidine WDR5-MLL1 Inhibitors: QSAR, Molecular Docking, and Molecular Dynamics Simulation

Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective

Identification of Pyrroloimidazoles As Potential Inhibitors of WDR5-WIN-Site by 3D-QSAR Molecular Simulation

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (wdr5)–mixed Lineage Leukemia (MLL) Protein–Protein Interaction

High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.

Molybdenum Disulfide@5-Carboxyfluorescein-probe Biosensor for Unamplified Specific Fragment Detection in Long Nucleic Acids Based on Magnetic Composite Probe-Actuated Deblocking of Secondary Structure.

Discovery of Non-peptide, Environmental Sensitive Fluorescent Probes for Imaging p53-MDM2 Interaction in Living Cell Line and Tissue Slice.

Highly Sensitive Protein Detection Based On A Novel Probe With Catalytic Activity Combined With A Signal Amplification Strategy: Assay Of Mdm2 For Cancer Staging

Design and Synthesis of a Novel Photoaffinity Probe for Labelling EGF Receptor Tyrosine Kinases